**Appendix 6b The results of the network meta-analysis of different dexamethasone regimens for the primary and secondary outcomes**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **BPD-36 weeks' PMA** |  |  |  |  |  |  |  |
| Placebo |  |  |  |  |  |  |  |
| 0.33 (0.09,1.03) | LHL |  |  |  |  |  |  |
| 0.26 (0.02,2.66) | 0.79 (0.05,11.49) | LHS |  |  |  |  |  |
| 0.65 (0.22,1.63) | 1.98 (0.40,9.07) | 2.49  (0.19,34.39) | LLL |  |  |  |  |
| **0.11 (0.02,0.41)** | 0.32 (0.04,2.03) | 0.41  (0.06,2.64) | **0.16**  **(0.03,0.92)** | EHL |  |  |  |
| 0.91 (0.19,4.24) | 2.75 (0.41,20.89) | 3.50  (0.22,67.88) | 1.39  (0.24,9.54) | **8.56 (1.14,82.62)** | EHS |  |  |
| **0.37 (0.16,0.67)** | 1.13 (0.27,4.20) | 1.43 (0.11,17.51) | 0.58  (0.20,1.50) | 3.44 (0.72,18.55) | 0.41  (0.07,1.97) | ELL |  |
| 0.77 (0.39,1.53) | 2.33 (0.62,9.97) | 2.98  (0.26,39.75) | 1.18  (0.39,4.41) | **7.24 (1.60,43.15)** | 0.85 (0.16,4.53) | 2.05 (0.89,6.38) | ELS |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **BPD-28 days’ PNA** |  |  |  |  |  |  |
| Placebo |  |  |  |  |  |  |
| 0.21  (0.03,1.05) | LHL |  |  |  |  |  |
| 0.47 (0.05,3.51) | 2.32 (0.16,33.02) | LHS |  |  |  |  |
| 0.27  (0.03,1.55) | 1.31  (0.10,14.92) | 0.56  (0.05,5.93) | LLL |  |  |  |
| **0.18 (0.06,0.49)** | 0.87  (0.12,7.04) | 0.38  (0.05, 3.07) | 0.67 (0.09, 5.94) | EHL |  |  |
| **0.21 (0.07,0.45)** | 1.01 (0.16,5.95) | 0.43  (0.05, 3.79) | 0.77 (0.13, 4.92) | 1.15 (0.28,4.06) | ELL |  |
| 0.98 (0.28,3.48) | 4.75 (0.65,46.96) | 2.07 (0.20, 27.46) | 3.63  (0.44,43.75) | **5.43 (1.16,30.46)** | **4.73 (1.19,26.54)** | ELS |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Death-36 weeks'PMA** |  |  |  |  |
| Placebo |  |  |  |  |
| 0.75 (0.28,1.99) | LLL |  |  |  |
| 0.18 (0.02,1.09) | 0.23 (0.02,1.82) | EHS |  |  |
| 1.06 (0.53,1.97) | 1.42  (0.54,3.54) | 6.04  (0.88,73.59) | ELL |  |
| 0.97 (0.24,3.89) | 1.29 (0.23,7.13) | 5.62 (0.55,91.01) | 0.92  (0.20,4.33) | ELS | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Death-28 days’ PNA** |  |  |  |  |  |  |
| Placebo |  |  |  |  |  |  |
| 0.18 (0.00,6.52) | LHL |  |  |  |  |  |
| 0.89 (0.11,6.22) | 5.07 (0.08,7264.00) | LLL |  |  |  |  |
| 1.59 (0.57,4.99) | 9.11 (0.22,10980.00) | 1.80 (0.21,19.99) | EHL |  |  |  |
| 1.93 (0.19,24.11) | 11.65 (0.15,19870.00) | 2.20 (0.11,53.75) | 1.21 (0.09,17.87) | EHS |  |  |
| 1.16 (0.35,3.44) | 6.51 (0.14,8216.00) | 1.31  (0.25,6.88) | 0.73 (0.14,3.09) | 0.59 (0.04,7.69) | ELL |  |
| 2.98 (0.40,27.85) | 18.00 (0.27,28800.00) | 3.39 (0.21,67.45) | 1.87 (0.18,21.18) | 1.55 (0.06,38.44) | 2.60 (0.26,33.12) | ELS |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **CP** |  |  |  |  |  |
| Placebo |  |  |  |  |  |
| 2.75 (0.88,8.01) | LHL |  |  |  |  |
| 0.10 (0.00,3.56) | 0.03  (0.00,1.46) | LHS |  |  |  |
| 0.87 (0.22,3.70) | 0.31 (0.06,2.08) | 9.01  (0.28, 4960.00) | LLL |  |  |
| 2.30 (0.41,13.22) | 0.82 (0.12,7.03) | 24.72  (0.42,18800.00) | 2.70  (0.27,23.60) | EHL |  |
| 0.53 (0.14,1.93) | 0.19 (0.04,1.10) | 5.68  (0.14,3377.00) | 0.62  (0.12,2.76) | 0.23 (0.03,2.01) | ELL |